KEYNOTE-555 Cohort B: Efficacy, safety, and PK of pembrolizumab (pembro) 400 mg every 6 weeks (Q6W) as 1L therapy for advanced melanoma - Jacobs, Conrad R.; Rapoport, Bernardo Leon; Chan, Sze Wai; Ruff, Paul; Arance, Ana Maria; Mujika, Karmele; Anderson, James Robert; Lala, Mallika; Jain, Lokesh; Akala, Omobolaji Oyekunle; Chartash, Elliot; Cohen, Graham Lawrence (Journal of clinical oncology, 2021)